Ensysce Biosciences (ENSCW) Net Cash Flow (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Net Cash Flow of -$414714.0 for Q3 2025, down 113.33% year-over-year from $3.1 million in Q3 2024, and up 50.68% quarter-over-quarter from -$840916.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Net Cash Flow (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Net Cash Flow data on file, last reported at -$414714.0 in Q3 2025.
- Net Cash Flow for Q3 2025 came in at -$414714.0, down 113.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.7 million (down 171.69% YoY), and the FY2024 annual result was $2.4 million, up 217.51% from the prior year.
- Net Cash Flow advanced to -$414714.0 in Q3 2025 per ENSCW's latest filing, from -$840916.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $7.7 million in Q2 2021 and troughed at -$4.7 million in Q2 2022.
- A 5-year average of $81060.4 and a median of -$449586.0 in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow plunged 11612.91% in 2022, then soared 231.69% in 2024.
- A 5-year view of Net Cash Flow shows it stood at $5.4 million in 2021, then sank by 125.01% to -$1.4 million in 2022, then surged by 74.86% to -$340777.0 in 2023, then sank by 91.19% to -$651515.0 in 2024, then soared by 36.35% to -$414714.0 in 2025.
- Business Quant data shows ENSCW's Net Cash Flow at -$414714.0 in Q3 2025, -$840916.0 in Q2 2025, and -$449586.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -414,714.00 |
| Sep 30, 2025 | -414,714.00 |
| Jun 30, 2025 | -840,916.00 |
| Jun 30, 2025 | -840,916.00 |
| Mar 31, 2025 | -449,586.00 |
| Mar 31, 2025 | -449,586.00 |
| Dec 31, 2024 | -651,515.00 |
| Dec 31, 2024 | -651,515.00 |
| Sep 30, 2024 | 3.11 Mn |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.36 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | -340,777.00 |
| Dec 31, 2023 | -340,777.00 |
| Sep 30, 2023 | -2.37 Mn |
| Sep 30, 2023 | -2.37 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Jun 30, 2023 | 2.41 Mn |